King Pharmaceuticals R & D

Icagen is a biotech company based in Durham, NC, specializing in ion channel drug discovery. With its Ion Channel Technology Platform, Icagen collaborates with renowned pharmaceutical companies to develop targeted therapeutics for various indications. Driven by a team of experienced scientists and experts, Icagen aims to advance medical discoveries through innovative applications of its proprietary technologies, offering a differentiated capability for high-value ion channel and transporter drug discovery programs.Generated from the website

Intas Pharmaceuticals Ltd. is a leading multinational pharmaceutical formulation development, manufacturing, and marketing company with a strong presence in over 85 countries worldwide. With a focus on creating good health, happiness, and hope, Intas is known for its excellence in the industry, with a billion-dollar turnover and a remarkable growth rate. Their dedicated research and development team works tirelessly to develop a diverse product portfolio that includes generics, oncology, and added-value products, with a significant investment in R&D year after year. Intas Pharmaceuticals is committed to transforming science into smiles and is a pioneer in biosimilars. Intas Pharmaceuticals Ltd. is a trusted global healthcare partner, providing innovative solutions to fortify immunity and fight infections. With a passion for research and development, Intas has established itself as a leader in the pharmaceutical industry, offering a wide range of high-quality products. Their state-of-the-art facilities and team of dedicated scientists and researchers ensure the development of world-class generics, oncology treatments, and added-value products. With a strong focus on international markets, particularly the highly regulated markets of the EU and US, Intas Pharmaceuticals continues to make a significant impact in the field of healthcare.Generated from the website

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule drugs that treat cancer, cardiovascular and autoimmune diseases and viral infections. BioCryst uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry and computer modeling. In structure-based drug design, scientists use detailed knowledge of the active sites of protein targets associated with particular diseases to design synthetic compounds that fight the disease. Structure-based drug design aims to create a molecule that will bind to the active site of a targeted enzyme, thereby preventing the normal chemical reaction and ultimately halting the progression of the disease. BioCryst was founded in 1986. The Company's stock is traded on the NASDAQ exchange under the symbol BCRX.